Selexys is a development stage biopharmaceutical company focused on the treatment of inflammatory and thrombotic diseases. ?The company has developed antibodies that block recruitment of white blood cells to activated endothelium and platelets. ?
Astellas is an international pharmaceutical company intensely focused on five key therapeutic areas: cardiology, dermatology, immunology, infectious disease, and urology.
Charlesson is an ocular pharmaceutical company that is developing therapeutics for various eye diseases, including wet and dry Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR), and Uveitis.
Biolytx Pharmaceuticals develops a novel antibiotic peptide for use in treatment of serious hospital-acquired infections, including those resistant to current antibiotics.
Wavetech, LLC is a privately held company specializing in research and development in emerging technology markets. Their emphasis is on electromagnetic technologies, including terahertz, artificial materials, and nondestructive evaluation.
Cytovance? Biologics adds significant value to biopharmaceutical development programs assisting companies to advance recombinant protein, antibody and cell-based therapeutic products rapidly and cost-effectively from the laboratory bench, through clinical development and to commercial launch in international markets.
Moleculera Labs provides personalized clinical testing services for individuals suspected of suffering from PANDAS/PANS, which are treatable neurologic conditions that may be associated with motor tics, obsessive compulsive disorders (OCD) and sometimes Autism Spectrum Disorders.
Jortan Pharmaceuticals Inc.?(JORTAN) was founded around aspartic protease inhibitors as potential diabetes therapeutics based on technology from the Oklahoma Medical Research Foundation (OMRF).
Pamlico Biopharma has developed personalized, targeted human antibody therapeutics against severe pneumonia that were created using patent-pending methodology from the Oklahoma Medical Research Foundation.
Hyalose specializes in Hyaluronic Acid production and application. The Emergent Technologies Inc. ?Sugar Companies? offer innovative technologies for producing Hyaluronic Acid, heparosan, and chondroitin in a reproducible and safe manner for a variety of medical and aesthetic uses. Hyalose was formed to commercialize unique recombinant technologies for producing Hyaluronic Acid, an important biomolecule for many healthcare and cosmetic applications.
Pure MHC focuses on HLA related immunology tools for vaccine development and immunotherapy validation.
Respiron is developing an antiviral drug, RN-1, to treat any existing and emerging strains of influenza virus. It can potentially cure flu symptoms in nearly 300 million people worldwide regardless of virus mutation.
Cosmetic Specialty Labs is skilled in developing high end, prestige skin care products, as well as custom formulated over the counter drugs.
Plymouth Pharmaceuticals, Inc. is a leading research and development company exploring safe, effective, oral therapies for inflammatory skin disorders.?Plymouth offers Rx and OTC products for psoriasis, eczema, acne and seborrhea dermatitis.
A subsidiary of Core Oncology, Mills Biopharmaceuticals, LLC (Mills) manufactures ProstaSeed? Iodine 125 brachytherapy seeds for the treatment of prostate cancer. Mills’ state-of-the-art 25,000 square foot manufacturing facility features highly automated machines and advanced manufacturing systems.
DormaTarg, Inc is a biotechnology company researching and developing therapeutic drugs for cancer recurrence prevention.
Kemmx Corporation is a start-up, biotechnology company pioneering the development and commercialization of targeted analgesics for chronic pain. Their topical analgesic formulations provide long lasting pain relief with minimal side effects.
The Lupus Multiplex Registry and Repository is finding the genes that cause lupus (also known as SLE or Systemic Lupus erythematosus). It works with families with one or more living lupus patients from across the US, Canada, Puerto Rico and the Virgin Islands, utilizing the genetic link between blood relatives to locate responsible genes.
Sensuli, LLC is developing a true once-a-day glucose-responsive insulin that may mimic a healthy human pancreas. Sensulin? may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.
Tetherex is developing a treatment for inflammatory and thrombotic diseases such as Crohn’s disease. Preclinical studies have shown a positive impact in remission of the disease with evidence of potentially reversing the disease process.